Search for other papers by María Dolores Rodríguez Arnao in
Google Scholar
PubMed
Search for other papers by Amparo Rodríguez Sánchez in
Google Scholar
PubMed
Search for other papers by Ignacio Díez López in
Google Scholar
PubMed
Search for other papers by Joaquín Ramírez Fernández in
Google Scholar
PubMed
Search for other papers by Jose Antonio Bermúdez de la Vega in
Google Scholar
PubMed
Search for other papers by Diego Yeste Fernández in
Google Scholar
PubMed
Search for other papers by María Chueca Guindulain in
Google Scholar
PubMed
Search for other papers by Raquel Corripio Collado in
Google Scholar
PubMed
Search for other papers by Jacobo Pérez Sánchez in
Google Scholar
PubMed
Search for other papers by Ana Fernández González in
Google Scholar
PubMed
Search for other papers by ECOS Spain Study Collaborative Investigator Group in
Google Scholar
PubMed
Introduction Since the 60s, GH has been the mainstay of treatment for children with GH deficiency (GHD) ( 1 ). With the discovery of recombinant human growth hormone (r-hGH), the treatment has been extended to other conditions, such as Turner
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
hormones are intact or properly replaced (4, 5, 6) . In addition, GH replacement in these subjects has been shown to reverse many of the abnormalities (7) . There is a paucity of data on recombinant human GH (r-hGH) replacement therapy in acromegaly
Search for other papers by Jessica S Jarmasz in
Google Scholar
PubMed
Search for other papers by Yan Jin in
Google Scholar
PubMed
Search for other papers by Hana Vakili in
Google Scholar
PubMed
Search for other papers by Peter A Cattini in
Google Scholar
PubMed
Introduction Human (h) growth hormone (GH) is synthesized and secreted in a pulsatile manner by somatotrophs located in the anterior pituitary ( 1 ). Following the successful isolation and purification of hGH in 1944, GH secretion in humans
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1141, DHU PROTECT, Paris, France
Search for other papers by Juliane Léger in
Google Scholar
PubMed
Search for other papers by Anne Fjellestad-Paulsen in
Google Scholar
PubMed
Search for other papers by Anne Bargiacchi in
Google Scholar
PubMed
Search for other papers by Catherine Doyen in
Google Scholar
PubMed
Search for other papers by Emmanuel Ecosse in
Google Scholar
PubMed
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1141, DHU PROTECT, Paris, France
Search for other papers by Jean-Claude Carel in
Google Scholar
PubMed
Search for other papers by Marie-France Le Heuzey in
Google Scholar
PubMed
are at least partially reversed during refeeding and recovery ( 19 ). The effects of supraphysiological levels of human GH on HV in these patients remain unclear. The administration of supraphysiological doses of hGH for four weeks is well tolerated
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Ichelle Maa van Roessel in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Boudewijn Bakker in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Search for other papers by Wassim Chemaitilly in
Google Scholar
PubMed
Guidelines ( 2 ). The treatment of GH deficiency relies on the use of human recombinant GH (hGH). This allows affected children to improve their linear growth and achieve better final height outcomes with added benefits on bone health, lean body mass and
Search for other papers by Robert Rapaport in
Google Scholar
PubMed
Search for other papers by Jan M Wit in
Google Scholar
PubMed
Search for other papers by Martin O Savage in
Google Scholar
PubMed
to rhGH. Genetic identification of IGF1R defects can be compared to published experience of rhGH therapy in such patients ( 73 ) rather than to non-specific responses to hGH in idiopathic SGA subjects. The new development of C-type natriuretic
Search for other papers by Niels B Dalsgaard in
Google Scholar
PubMed
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Lærke S Gasbjerg in
Google Scholar
PubMed
Search for other papers by Laura S Hansen in
Google Scholar
PubMed
Search for other papers by Dennis S Nielsen in
Google Scholar
PubMed
Search for other papers by Torben S Rasmussen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Search for other papers by Filip K Knop in
Google Scholar
PubMed
Committee of the Capital Region of Denmark (record no. H-17007893). The study was registered at clinicaltrials.gov (ID: NCT03241303) and the Danish Data Protection Agency (local no. HGH-2018-041, I-Suite no. 6.802). Research design and experimental
Search for other papers by Kennett Sprogøe in
Google Scholar
PubMed
Search for other papers by Eva Mortensen in
Google Scholar
PubMed
Search for other papers by David B Karpf in
Google Scholar
PubMed
Search for other papers by Jonathan A Leff in
Google Scholar
PubMed
://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004975-37/results ) 66 Kang J Kim P Kwak EH Xu M-Y Han O Kim Y Jung SY Kwon S Huh Y Chapel S . 6 month results of a phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a long acting r-Hgh-HMbib1
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
significant. GraphPad Prism 7.0 software and R Core Team software (Vienna, Austria) were used to perform those analysis. Results Population description and GHD status Between March 2006 and January 2022, 156 GHD female patients presented with GHD
Search for other papers by Justyna Modrzynska in
Google Scholar
PubMed
Search for other papers by Christine F Klein in
Google Scholar
PubMed
Search for other papers by Kasper Iversen in
Google Scholar
PubMed
Search for other papers by Henning Bundgaard in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Bolette Hartmann in
Google Scholar
PubMed
Search for other papers by Maike Mose in
Google Scholar
PubMed
Search for other papers by Nikolaj Rittig in
Google Scholar
PubMed
Search for other papers by Niels Møller in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Nicolai J Wewer Albrechtsen in
Google Scholar
PubMed
surgery within 14 days prior to the study inclusion were excluded from the study population. All patients provided written informed consent. The study protocol was approved by the Data Protection Agency (HGH-2015-010, I-suite no: 03923) and the Danish